CCM
AXDX

Cupps Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Cupps Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-10,968
Closed -$2.83M – 183
2015
Q2 		$2.83M Buy
+10,968
New +$2.62M 0.27% 103

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.44B AUM 24.34% 1-Year Est. Return

Cupps Capital Management's AXDX Position: Q3 2015 in Review

Cupps Capital Management sold out of Accelerate Diagnostics (AXDX) in Q3 2015, closing a stake of 10,968 shares — an estimated $2.83M sold.

Cupps Capital Management first reported a position in AXDX in Q2 2015 and held it in 1 quarter. The position peaked at $2.83M in Q2 2015. 88 funds tracked by Wall St. Rank hold AXDX as of Q3 2015.

  • Cupps Capital Management reported no remaining Accelerate Diagnostics position as of Q3 2015 after selling out during the quarter.
  • Cupps Capital Management sold 10,968 Accelerate Diagnostics shares in Q3 2015, an estimated $2.83M.
  • Cupps Capital Management first reported a position in Accelerate Diagnostics in Q2 2015 and held it in 1 quarter.
  • Cupps Capital Management's Accelerate Diagnostics position peaked at $2.83M in Q2 2015.
  • 88 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2015.

Based on Cupps Capital Management's 13F filing for Q3 2015, filed 12 Nov 2015.